Australia - English - Department of Health (Therapeutic Goods Administration)

rad data australia pty ltd - melatonin -

Australia - English - Department of Health (Therapeutic Goods Administration)

venlafaxine -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - venlafaxine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - venlafaxine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - venlafaxine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - venlafaxine hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - melatonin 2mg;  ;   - modified release tablet - 2 mg - active: melatonin 2mg     excipient: ammonio methacrylate copolymer calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate purified talc - monotherapy for the short term treatment (up to 13 weeks) of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 10mg;   - modified release capsule - 10 mg - active: methylphenidate hydrochloride 10mg   excipient: ammonio methacrylate copolymer gelatin macrogol 6000 methacrylic acid copolymer purified talc sugar spheres tekprint tan sw-8010 titanium dioxide triethyl citrate - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 20mg;   - modified release capsule - 20 mg - active: methylphenidate hydrochloride 20mg   excipient: ammonio methacrylate copolymer gelatin methacrylic acid copolymer type a-methacrylate acid-methacrylate copolymer 1:1, dry powder macrogol 6000 purified talc sugar spheres titanium dioxide triethyl citrate - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - methylphenidate hydrochloride 30mg;   - modified release capsule - 30 mg - active: methylphenidate hydrochloride 30mg   excipient: ammonio methacrylate copolymer gelatin methacrylic acid copolymer type a/methacrylic acid methacrylate copolymer 1:1, dry powder iron oxide yellow macrogol 6000 purified talc sugar spheres titanium dioxide triethyl citrate - ritalin/ritalin sr is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older. ritalin la is indicated in the treatment of attention-deficit/hyperactivity disorder in children aged 6 years or older and in adults. ritalin/ritalin sr is indicated for the treatment of narcolepsy in adults. symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.